Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Larimar Therapeutics Inc | LRMR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 8.00 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 8.00 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.18 - 13.68 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 8.00 | USD |
Larimar Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 63.16M | 63.80M | - | 0 | -36.95M | -0.58 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Larimar Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LRMR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.09 | 8.27 | 6.8811 | 7.64 | 467,813 | 0.91 | 12.83% |
| 1 Month | 7.86 | 8.678 | 6.8811 | 7.71 | 560,467 | 0.14 | 1.78% |
| 3 Months | 9.92 | 10.24 | 5.91 | 7.74 | 499,111 | -1.92 | -19.35% |
| 6 Months | 3.53 | 13.68 | 3.34 | 8.68 | 470,418 | 4.47 | 126.63% |
| 1 Year | 3.82 | 13.68 | 2.18 | 7.17 | 332,705 | 4.18 | 109.42% |
| 3 Years | 8.10 | 15.2581 | 1.53 | 6.12 | 216,124 | -0.10 | -1.23% |
| 5 Years | 12.00 | 25.87 | 1.53 | 6.97 | 178,865 | -4.00 | -33.33% |
Larimar Therapeutics Description
| Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. |
